BMC Cancer (Feb 2024)

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma

  • Yuchong Yang,
  • Hui Tan,
  • Yao Lu,
  • Jipeng Mei,
  • Mengqi Zhang,
  • Ming Bai,
  • Xia Wang,
  • Shaohua Ge,
  • Tao Ning,
  • Le Zhang,
  • Zhi Ji,
  • Jingjing Duan,
  • Yansha Sun,
  • Feixue Wang,
  • Rui Liu,
  • Hongli Li,
  • Ting Deng

DOI
https://doi.org/10.1186/s12885-024-11968-6
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Increasing evidence has showed that inflammatory biomarkers, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and fibrinogen can be used as predictors in the prognosis of esophageal squamous cell carcinoma (ESCC). The aim of this study was to explore prognostic value of these biomarkers and evaluate the clinicopathological and prognostic significance of combined score based on plasma fibrinogen and platelet-lymphocyte ratio (F-PLR score). Methods A total of 506 patients with ESCC were enrolled in this study. Harrell’s concordance index (c-index) was used to determine the optimal cut-off values of these markers and evaluate their prognostic significance. The relationship between factors with survival rates (including overall survival [OS] and disease-free survival [DFS]) was explored by Kaplan-Meier curve, univariate analysis and multivariate cox hazard analysis. Results Our result indicated that high F-PLR score was significantly associated with longer tumor length and deeper depth of tumor invasion (p < 0.01). The result of Cox multivariable analysis showed that F-PLR score was an independent prognostic factor for OS (p = 0.002) and DFS (p = 0.003). In addition, F-PLR score presented the greater c-index values for OS and DFS compared with NLR, PLR and fibrinogen level. Our result also showed that the c-index values for OS and DFS were both greater in TNM + F-PLR than those in TNM stage alone. Conclusions In conclusion, F-PLR score is a predictive biomarker for prognosis in patients with ESCC.

Keywords